Skip to main content
Year archive

Spexis AG — 2019 filings

All 21 regulatory filings released by Spexis AG (SPEX) in 2019, sourced directly from the official regulator.

21 Filings
2019 Period
2019 filings (21)
Filing Released Lang
Polyphor announces changes to its Board of Directors
Board/Management Information
2019-11-20 English
Polyphor and the University of Zurich announces publication in 'Nature' of the unique mechanism of action of a new class of antibiotics.
Regulatory Filings
2019-10-23 English
Polyphor to present at the H.C. Wainwright Global Investment Conference
Report Publication Announcement
2019-09-04 English
Polyphor announces financial results for the first half 2019 and realigns strategy
Earnings Release H1 2019
2019-09-04 English
Polyphor to host a Key Opinion Leader Meeting in New York on novel approach-es to the treatment of metastatic breast cancer
Regulatory Filings
2019-08-20 English
Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options
Regulatory Filings
2019-07-17 English
Polyphor appoints Frank Weber as new Chief Medical and Development Officer
Board/Management Information
2019-06-27 English
Polyphor to present its antibiotic programs at the American Society of Microbiology (ASM) Microbe 2019 Conference
Report Publication Announcement
2019-06-20 English
Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer
Regulatory Filings
2019-06-19 English
Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Regulatory Filings
2019-06-07 English
Polyphor and the University of Zurich receive an award from Innosuisse to accelerate the development of a new class of antibiotics inhibiting the LPS transport pathway
Environmental & Social Information
2019-05-29 English
Polyphor announces presentation of new survival data on balixafortide at the ASCO Annual Meeting 2019
Legal Proceedings Report
2019-05-17 English
Polyphor temporarily halts enrollment in the Phase III studies of murepavadin for the treatment of patients with nosocomial pneumonia
Legal Proceedings Report
2019-05-09 English
Polyphor presents new data at ECCMID from its lead antibiotic murepavadin and the new OMPTA POL7306
Earnings Release Q2 2019
2019-04-17 English
Polyphor announces enrollment of first patient in PRISM-UDR - the second, FDA agreed - Phase III clinical trial for murepavadin in patients with nosocomial pneumonia
Regulatory Filings
2019-04-16 English
Polyphor shareholders approve all motions proposed by the Board of Directors at the Annual General Meeting
AGM Information
2019-04-12 English
Polyphor's antibiotic murepavadin receives US FDA Qualified Infectious Disease Product designation in four new indications
Regulatory Filings
2019-04-12 English
Polyphor appoints Gokhan Batur as Chief Commercial Officer
Board/Management Information
2019-04-09 English
Polyphor to present data on murepavadin and its lead preclinical compound of its novel class of Gram-negative antibiotics at the 29th European Congress of Clinical Microbiology and Infectious Diseases
Regulatory Filings
2019-04-04 English
Polyphor announces financial results for the full-year 2018
Earnings Release FY 2018
2019-03-15 English
Polyphor awarded grant from CARB-X of up to $5.6M to support development of novel antibiotic against multi-drug resistant Gram-negative pathogens
Capital/Financing Update
2019-02-04 English